文献速递造血干细胞移植与细胞治疗

血液恶性肿瘤单倍体移植后特发性炎性脱髓鞘病的临床危险因素与预后模型

Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies.
PubMed 文献 · Am J Hematol · 2021-08-17

该回顾性研究纳入2008—2019年单中心4532例接受单倍体造血干细胞移植(haplo-HSCT)的血液恶性肿瘤患者,184例(4.1%)发生中枢神经系统特发性炎性脱髓鞘病(IIDDs)。II-IV级急性GVHD(p<0.001)和慢性GVHD(p=0.009)是IIDDs的危险因素;基于CMV感染、EBV感染、IgG合成和脊髓病变构建的预后模型在内部验证队列AUC为0.864(95%CI: 0.803-0.925),外部验证队列AUC为0.871(95%CI: 0.806-0.931)。

要点

  • haplo-HSCT后IIDDs发生率为4.1%,II-IV级aGVHD和cGVHD是危险因素。
  • 预后模型纳入CMV感染、EBV感染、IgG合成和脊髓病变四个预测因子。
  • 模型内部验证AUC 0.864(95%CI: 0.803-0.925),外部验证AUC 0.871(95%CI: 0.806-0.931)。

核心结论

  • II-IV级aGVHD和cGVHD是haplo-HSCT后发生IIDDs的危险因素。
  • 基于CMV感染、EBV感染、IgG合成和脊髓病变的预后模型可预测IIDDs患者预后。

研究设计与样本

  • 回顾性研究,2008—2019年单中心4532例接受haplo-HSCT的血液恶性肿瘤患者。
  • 184例(4.1%)发生移植后IIDDs,按移植时间分为推导队列和验证队列。

主要发现

  • II-IV级aGVHD(p<0.001)和cGVHD(p=0.009)是发生IIDDs的危险因素。
  • 预后模型内部验证AUC为0.864(95%CI: 0.803-0.925),外部验证AUC为0.871(95%CI: 0.806-0.931)。
  • 校准曲线显示预测结局与观察结局高度一致。
  • 决策曲线分析提示IIDD患者可从预后模型的临床应用获益。

关键数值与推荐

  • 预后模型纳入四个预测因子:CMV感染、EBV感染、IgG合成(IgG-syn)和脊髓病变。
  • 内部验证队列AUC 0.864(95%CI: 0.803-0.925),外部验证队列AUC 0.871(95%CI: 0.806-0.931)。

临床怎么用

  • 识别allo-HSCT后预后不良的IIDD患者可能有助于及时治疗并改善生存与结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idiopathic inflammatory demyelinating diseases (IIDDs) of the central nervous system (CNS) are rare but serious neurological complications of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). However, the risk factors and a method to predict the prognosis of post-transplantation CNS IIDDs are not available. This retrospective study first reviewed data from 4532 patients who received haplo-HSCT during 2008-2019 in our center, and 184 patients (4.1%) with IIDDs after haplo-HSCT were identified. Grades II to IV acute graft-versus-host disease (aGVHD) (p < 0.001) and chronic GVHD (cGVHD) (p = 0.009) were identified as risk factors for developing IIDDs after haplo-HSCT. We then divided the 184 IIDD patients into a derivation cohort and validation cohort due to transplantation time to develop and validate a model for predicting the prognosis of IIDDs. In the multivariate analysis of the derivation cohort, four candidate predictors were entered into the final prognostic model: cytomegalovirus (CMV) infection, Epstein-Barr virus (EBV) infection, IgG synthesis (IgG-syn) and spinal cord lesions. The prognostic model had an area under the receiver operating characteristic curve of 0.864 (95% CI: 0.803-0.925) in the internal validation cohort and 0.871 (95% CI: 0.806-0.931) in the external validation cohort. The calibration plots showed a high agreement between the predicted and observed outcomes. Decision curve analysis indicated that IIDD patients could benefit from the clinical application of the prognostic model. The identification of IIDD patients after allo-HSCT who have a poor prognosis might allow timely treatment and improve patient survival and outcomes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Deng RX, Wu YJ, Xu LP, et al. Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. Am J Hematol. 2021. PMID: 34350623. doi:10.1002/ajh.26312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。